Get the Stockscreener App
17.90
0.62%
0.11
After Hours:
18.60
0.70
+3.91%
Elanco Animal Health Inc stock is traded at $17.90, with a volume of 3.07M.
It is up +0.62% in the last 24 hours and up +19.97% over the past month.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
See More
Previous Close:
$17.79
Open:
$17.82
24h Volume:
3.07M
Relative Volume:
0.56
Market Cap:
$8.89B
Revenue:
$4.45B
Net Income/Loss:
$205.00M
P/E Ratio:
44.75
EPS:
0.4
Net Cash Flow:
$372.00M
1W Performance:
+2.17%
1M Performance:
+19.97%
6M Performance:
+60.83%
1Y Performance:
+23.45%
1-Day Range:
$17.73
$17.98
1-Week Range:
$17.33
$18.00
52-Week Range:
$8.02
$18.09
Elanco Animal Health Inc Stock (ELAN) Company Profile
Name
Elanco Animal Health Inc
Sector
Phone
877-352-6261
Address
2500 INNOVATION WAY, GREENFIELD
Compare ELAN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELAN
Elanco Animal Health Inc
|
17.90 | 8.79B | 4.45B | 205.00M | 372.00M | 0.40 |
|
ZTS
Zoetis Inc
|
154.79 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.88 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.63 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.15 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
309.22 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-17-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jun-26-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-09-24 | Initiated | UBS | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Market Perform |
| Sep-19-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-05-24 | Upgrade | Stifel | Hold → Buy |
| Dec-19-23 | Initiated | Jefferies | Buy |
| Dec-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
| Apr-20-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-18-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-16-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Sell |
| Jul-12-22 | Initiated | Piper Sandler | Neutral |
| Nov-18-21 | Initiated | Morgan Stanley | Overweight |
| Oct-28-21 | Downgrade | Stifel | Buy → Hold |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jun-15-21 | Upgrade | Cleveland Research | Underperform → Neutral |
| May-11-21 | Upgrade | Barclays | Underweight → Equal Weight |
| May-11-21 | Upgrade | Gabelli & Co | Hold → Buy |
| Apr-15-21 | Initiated | Stifel | Buy |
| Mar-22-21 | Downgrade | Gabelli & Co | Buy → Hold |
| Feb-26-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-09-20 | Downgrade | Argus | Buy → Hold |
| Nov-09-20 | Downgrade | Barclays | Overweight → Underweight |
| Aug-20-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-13-20 | Resumed | Credit Suisse | Neutral |
| Aug-04-20 | Resumed | Goldman | Buy |
| Jul-27-20 | Downgrade | Cleveland Research | Neutral → Underperform |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-20 | Initiated | Raymond James | Mkt Perform |
| Dec-19-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Nov-07-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-19 | Initiated | Barclays | Overweight |
| Aug-26-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-15-19 | Upgrade | UBS | Sell → Neutral |
| May-23-19 | Initiated | Guggenheim | Neutral |
| Mar-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-13-19 | Resumed | Morgan Stanley | Equal-Weight |
| Feb-12-19 | Initiated | William Blair | Mkt Perform |
| Jan-23-19 | Initiated | UBS | Sell |
| Jan-15-19 | Initiated | Argus | Buy |
| Oct-15-18 | Initiated | Morgan Stanley | Equal-Weight |
View All
Elanco Animal Health Inc Stock (ELAN) Latest News
Exclusive Veterinary Oncology Market Report with Detailed Analysis | Zoetis Inc., Elanco, AB Science - openPR.com
Veterinary Oncology Market Growth Fueled by Rising Pet Cancer - openPR.com
Elanco Animal Health: Innovating for Sustainable Growth - AInvest
Sentiment Turns Positive on Elanco Animal Health Incorporated — Reversal Ahead2025 Retail Activity & Real-Time Market Sentiment Alerts - sundaytimes.kr
Elanco CEO Jeff Simmons: Innovation and Sustainability Drive Long-Term Growth - ACCESS Newswire
Can Elanco Animal Health Incorporated outperform under higher oil pricesEarnings Beat & Reliable Price Action Trade Plans - sundaytimes.kr
Elanco Animal Health's (NYSE:ELAN) Solid Earnings May Rest On Weak Foundations - Yahoo Finance
Leerink Partnrs Issues Negative Outlook for ELAN Earnings - MarketBeat
Elanco (ELAN) Q2 Revenue Jumps 5% - AOL.com
Elanco Animal Health stock hits 52-week high at 17.85 USD - Investing.com Canada
Piper Sandler Issues Positive Forecast for Elanco Animal Health (NYSE:ELAN) Stock Price - MarketBeat
5 Insightful Analyst Questions From Elanco’s Q2 Earnings Call - FinancialContent
Nuveen LLC Makes New Investment in Elanco Animal Health Incorporated (NYSE:ELAN) - MarketBeat
Elanco Animal Health (NYSE:ELAN) Stock Price Expected to Rise, UBS Group Analyst Says - MarketBeat
Elanco spearheads Nutrition Secure Indianapolis initiative to provide food aid - Inside INdiana Business
Dogs Vaccines Market Exclusive Report with Detailed Study - openPR.com
Cary Street Partners Financial LLC Buys New Shares in Elanco Animal Health Incorporated (NYSE:ELAN) - MarketBeat
Elanco Animal Health Posts Robust Q2 Earnings, Exceeds Guidance with Strong Organic Growth and Innovation - AInvest
Elanco Animal Health’s Q2 Earnings Call Highlights - TipRanks
Elanco’s Q2 2025 Return to Profitability Signals Growth - Zenopa
Leerink Partners Keeps Buy Rating on Elanco Animal Health with $20 Price Target - AInvest
ELAN Q2 Deep Dive: Innovation and Execution Drive Raised Full-Year Outlook - FinancialContent
Elanco Animal Health (NYSE:ELAN) Posts Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Elanco Animal Health (NYSE:ELAN) Releases Q3 2025 Earnings Guidance - MarketBeat
Investors in Elanco Animal Health (NYSE:ELAN) From Five Years Ago Are Still Down 36%, Even After 18% Gain This Past Week - 富途牛牛
Elanco Animal Health: Piper Sandler raises PT to $18 from $12, maintains Neutral rating. - AInvest
Price Consolidation Hints at Upcoming Move in Elanco Animal Health IncorporatedReversal Alert Based on RSI Indicator Confirmed - metal.it
Arkadios Wealth Advisors Makes New Investment in Elanco Animal Health Incorporated (NYSE:ELAN) - MarketBeat
Elanco (ELAN) Jumps 19.7% to Record High on Earnings Boost - MSN
Elanco Animal Health Surges 9% on Q2 Results and Optimistic Full-Year Forecast - AInvest
Elanco Animal Health: Analyst Sentiment Analysis and 12-Month Price Targets - AInvest
Elanco Animal Health Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Elanco Animal Health Incorporated (NYSE:ELAN) Q2 2025 Earnings Call Transcript - Insider Monkey
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX) and Elanco Animal Health (ELAN) - The Globe and Mail
Elanco Animal Health (ELAN) Gets a Buy from Bank of America Securities - The Globe and Mail
Elanco Animal Health Reports Strong Q2 2025 Results - The Globe and Mail
Chart based analysis of Elanco Animal Health Incorporated trendsTrend Confirmation Scanner with Entry Focus - Newser
ICYMI: Elanco Shares Jump After 2Q Beat-and-Raise Results - iHeart
Elanco Puppy Virus Treatment Expanded With USDA Approval - InkFreeNews.com
UBS Raises PT to $19 for Elanco Animal Health Amid Bullish Outlook - AInvest
A Quick Look at Today's Ratings for Elanco Animal Health(ELAN.US), With a Forecast Between $15 to $21 - 富途牛牛
An Intrinsic Calculation For Elanco Animal Health Incorporated (NYSE:ELAN) Suggests It's 36% Undervalued - Yahoo Finance
Elanco Animal Health shares fall 1.40% premarket after beating Q2 revenue estimates and raising FY guidance. - AInvest
What institutional flow reveals about Elanco Animal Health IncorporatedStrong Buy Signal Summary with Entry Zone - Newser
Elanco Animal Health Inc (ELAN) Q2 2025 Earnings Call Highlights: Strong Pet Health Growth and ... By GuruFocus - Investing.com Canada
Elanco Animal Health 2025 Q2 Earnings Strong Performance as Net Income Surges 122% - AInvest
Elanco Raises 2025 Innovation Revenue Outlook to $720M-$800M, Signals Margin Expansion Through New Launches. - AInvest
10 Hot Stocks Making Winning Look Easy - Insider Monkey
Elanco's Q2 2025 Earnings Call: Unraveling Key Contradictions in FX Impact, Innovation Growth, and Margin Dynamics - AInvest
Elanco Animal Health Q2 2025: Innovation-Driven Growth and Accelerated Deleveraging Justify a Buy Rating - AInvest
Elanco Animal Health shares fall 1.55% after-hours despite beating Q2 revenue estimates and raising FY guidance. - AInvest
Elanco Animal Health Inc Stock (ELAN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.73%
2.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):